BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23421558)

  • 1. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison.
    Brusa D; Simone M; Gontero P; Spadi R; Racca P; Micari J; Degiuli M; Carletto S; Tizzani A; Matera L
    Int J Urol; 2013 Oct; 20(10):971-8. PubMed ID: 23421558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells, CD14(+) monocytes, and CD16(-) dendritic cells.
    Almeida J; Bueno C; Algueró MC; Sanchez ML; de Santiago M; Escribano L; Díaz-Agustín B; Vaquero JM; Laso FJ; San Miguel JF; Orfao A
    Clin Immunol; 2001 Sep; 100(3):325-38. PubMed ID: 11513546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.
    Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K
    Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
    Valenti R; Huber V; Filipazzi P; Pilla L; Sovena G; Villa A; Corbelli A; Fais S; Parmiani G; Rivoltini L
    Cancer Res; 2006 Sep; 66(18):9290-8. PubMed ID: 16982774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
    Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
    PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.
    Vuk-Pavlović S; Bulur PA; Lin Y; Qin R; Szumlanski CL; Zhao X; Dietz AB
    Prostate; 2010 Mar; 70(4):443-55. PubMed ID: 19902470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment.
    Väyrynen JP; Haruki K; Väyrynen SA; Lau MC; Dias Costa A; Borowsky J; Zhao M; Ugai T; Kishikawa J; Akimoto N; Zhong R; Shi S; Chang TW; Fujiyoshi K; Arima K; Twombly TS; Da Silva A; Song M; Wu K; Zhang X; Chan AT; Nishihara R; Fuchs CS; Meyerhardt JA; Giannakis M; Ogino S; Nowak JA
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
    Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
    Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD33
    Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
    Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
    Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
    Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.
    Xiu B; Lin Y; Grote DM; Ziesmer SC; Gustafson MP; Maas ML; Zhang Z; Dietz AB; Porrata LF; Novak AJ; Liang AB; Yang ZZ; Ansell SM
    Blood Cancer J; 2015 Jul; 5(7):e328. PubMed ID: 26230952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
    Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
    Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
    Tian T; Gu X; Zhang B; Liu Y; Yuan C; Shao L; Guo Y; Fan K
    Cancer Biomark; 2015; 15(4):425-32. PubMed ID: 25792471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors.
    Kvistborg P; Bechmann CM; Pedersen AW; Toh HC; Claesson MH; Zocca MB
    Vaccine; 2009 Dec; 28(2):542-7. PubMed ID: 19837091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CD14
    Mengos AE; Gastineau DA; Gustafson MP
    Front Immunol; 2019; 10():1147. PubMed ID: 31191529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma.
    Yuan XK; Zhao XK; Xia YC; Zhu X; Xiao P
    J Int Med Res; 2011; 39(4):1381-91. PubMed ID: 21986138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating CD14
    Stenzel AE; Abrams SI; Joseph JM; Goode EL; Tario JD; Wallace PK; Kaur D; Adamson AK; Buas MF; Lugade AA; Laslavic A; Taylor SE; Orr B; Edwards RP; Elishaev E; Odunsi K; Mongiovi JM; Etter JL; Winham SJ; Kaufmann SH; Modugno F; Moysich KB
    Am J Reprod Immunol; 2021 Mar; 85(3):e13343. PubMed ID: 32905653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma.
    Gustafson MP; Lin Y; Bleeker JS; Warad D; Tollefson MK; Crispen PL; Bulur PA; Harrington SM; Laborde RR; Gastineau DA; Leibovich BC; Cheville JC; Kwon ED; Dietz AB
    Clin Cancer Res; 2015 Sep; 21(18):4224-33. PubMed ID: 25999436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury.
    Walsh DS; Thavichaigarn P; Pattanapanyasat K; Siritongtaworn P; Kongcharoen P; Tongtawe P; Yongvanitchit K; Jiarakul N; Dheeradhada C; Pearce FJ; Wiesmann WP; Webster HK
    J Surg Res; 2005 Dec; 129(2):221-30. PubMed ID: 16045935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.